Raising the quality of rheumatology management recommendations: lessons from the EULAR process 10 years after provision of standard operating procedures
Alexandra N. Colebatch-Bourn(Yeovil District Hospital NHS Foundation Trust), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Nigel Arden(Nuffield Orthopaedic Centre), Philip G. Conaghan(University of Leeds), Cyrus Cooper(University Hospital Southampton NHS Foundation Trust), Maxime Dougados(Délégation Paris 5)
Cited by 6
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
|European Heart Journal|2021|1.7k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k